keyword
https://read.qxmd.com/read/38665845/improving-olaparib-exposure-to-optimize-adverse-effects-management
#21
JOURNAL ARTICLE
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt
BACKGROUND: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. OBJECTIVES: This work aimed to describe the pharmacokinetics/pharmacodynamics (PK/PD) relationship between olaparib plasma concentrations and common adverse effects (i.e. anaemia and hypercreatininaemia), in a real-life setting, to propose a target concentration for therapeutic drug monitoring...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38653508/epirubicin-for-the-treatment-of-sepsis-and-septic-shock-epos-1-study-protocol-for-a-randomised-placebo-controlled-phase-iia-dose-escalation-trial
#22
RANDOMIZED CONTROLLED TRIAL
Daniel Thomas-Rüddel, Michael Bauer, Luís Ferreira Moita, Christiane Helbig, Peter Schlattmann, Johannes Ehler, Tim Rahmel, Patrick Meybohm, Matthias Gründling, Heiko Schenk, Thomas Köcher, Frank M Brunkhorst, Markus Gräler, Ann-Julika Heger, Sebastian Weis
INTRODUCTION: Sepsis remains the major cause of death among hospitalised patients in intensive care. While targeting sepsis-causing pathogens with source control or antimicrobials has had a dramatic impact on morbidity and mortality of sepsis patients, this strategy remains insufficient for about one-third of the affected individuals who succumb. Pharmacological targeting of mechanisms that reduce sepsis-defining organ dysfunction may be beneficial. When given at low doses, the anthracycline epirubicin promotes tissue damage control and lessens the severity of sepsis independently of the host-pathogen load by conferring disease tolerance to infection...
April 22, 2024: BMJ Open
https://read.qxmd.com/read/38653449/early-erythroferrone-levels-can-predict-the-long-term-haemoglobin-responses-to-erythropoiesis-stimulating-agents
#23
JOURNAL ARTICLE
Peng Xu, Raymond S M Wong, Xiaoyu Yan
BACKGROUND AND PURPOSE: Our previous study reported that erythroferrone (ERFE), a newly identified hormone produced by erythroblasts, responded to recombinant human erythropoietin (rHuEPO) sensitively but its dynamics was complicated by double peaks and circadian rhythm. This study intends to elucidate the underlying mechanisms for the double peaks of ERFE dynamics and further determine whether early ERFE measurements can predict haemoglobin responses to rHuEPO. EXPERIMENTAL APPROACH: By using the purified recombinant rat ERFE protein and investigating its deposition in rats, the production of ERFE was deconvoluted...
April 23, 2024: British Journal of Pharmacology
https://read.qxmd.com/read/38650393/evaluation-of-omadacycline-regimens-for-community-acquired-bacterial-pneumonia-patients-infected-with-staphylococcus-aureus-by-pharmacokinetic-pharmacodynamic-analysis
#24
JOURNAL ARTICLE
Gaoqi Xu, Xin Liu, Jiaqi Wang, Yuqing Mei, Dihong Yang, Chaoneng He, Like Zhong, Junfeng Zhu, Haiying Ding, Luo Fang
Omadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with Staphylococcus aureus , including Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concentration (MIC) data, and in vivo PK/PD targets to calculate the probability of target attainment (PTA) and cumulative fraction of response (CFR) values for different dose regimens against MRSA and MSSA in CABP patients...
April 22, 2024: Journal of Chemotherapy
https://read.qxmd.com/read/38643185/pharmacokinetic-pharmacodynamic-evaluation-of-gamithromycin-against-rabbit-pasteurellosis
#25
JOURNAL ARTICLE
Xin-Yi Wei, Jing Zhang, Yin Zhang, Wen-Zhen Fu, Long-Gen Zhong, Yi-Duo Pan, Jian Sun, Xiao-Ping Liao, Ya-Hong Liu, Yu-Feng Zhou
BACKGROUND: Gamithromycin is an effective therapy for bovine and swine respiratory diseases but not utilized for rabbits. Given its potent activity against respiratory pathogens, we sought to determine the pharmacokinetic profiles, antimicrobial activity and target pharmacokinetic/pharmacodynamic (PK/PD) exposures associated with therapeutic effect of gamithromycin against Pasteurella multocida in rabbits. RESULTS: Gamithromycin showed favorable PK properties in rabbits, including high subcutaneous bioavailability (86...
April 20, 2024: BMC Veterinary Research
https://read.qxmd.com/read/38627763/impact-of-attaining-aggressive-vs-conservative-pk-pd-target-on-the-clinical-efficacy-of-beta-lactams-for-the-treatment-of-gram-negative-infections-in-the-critically-ill-patients-a-systematic-review-and-meta-analysis
#26
JOURNAL ARTICLE
Milo Gatti, Pier Giorgio Cojutti, Federico Pea
BACKGROUND: To perform a systematic review with meta-analysis with the dual intent of assessing the impact of attaining aggressive vs. conservative beta-lactams PK/PD target on the clinical efficacy for treating Gram-negative infections in critical patients, and of identifying predictive factors of failure in attaining aggressive PK/PD targets. METHODS: Two authors independently searched PubMed-MEDLINE and Scopus database from inception to 23rd December 2023, to retrieve studies comparing the impact of attaining aggressive vs...
April 16, 2024: Critical Care: the Official Journal of the Critical Care Forum
https://read.qxmd.com/read/38623974/preclinical-pharmacokinetics-and-pharmacology-study-of-rc98-a-programmed-cell-death-ligand-1-monoclonal-antibody-in-cynomolgus-monkeys
#27
JOURNAL ARTICLE
Ling Wang, Qiaoning Li, Chenglian Deng, Zhihao Liu, Fang Wang, Shenjun Li, Lihou Dong, Jing Jiang
INTRODUCTION: RC98 is the monoclonal antibody against Programmed Cell Death Ligand 1 (PD-L1). Relevant reports have confirmed that the influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined. OBJECTIVE: This study aimed to design a Pharmacokinetics/Pharmacology (PK/PD) study of RC98 in normal cynomolgus monkeys to research the effect on the immune system...
April 15, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38621948/-effects-of-tetramethylpyrazine-on-pharmacokinetics-in-plasma-and-brain-dialysate-and-neuropathic-pain-in-rat-model-of-spared-sciatic-nerve-injury
#28
JOURNAL ARTICLE
Zhi Chen, Dan-Dan DU, Ya Gao, Jun-Miao Chen, Cui-Ping Wei, Xiao-Gang Weng, Jian Sun, Xin-Yuan Wang, Zhi-Guo Wang, Mei-Yu Zhang
This study aims to explore the effects of tetramethylpyrazine(TMP) on pharmacokinetics in plasma and brain dialysate and neuropathic pain in the rat model of partial sciatic nerve injury(SNI), and to investigate the correlation between the analgesic effect of TMP and its concentrations in the plasma and brain dialysate. Male SD rats were randomized into Sham, SNI, and SNI+TMP groups. Mechanical stimulation with von frey filaments and cold spray method were employed to evaluate the mechanical sensitivity and cold sensitivity of rats...
March 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://read.qxmd.com/read/38619005/characterization-of-structural-biochemical-pharmacokinetic-and-pharmacodynamic-properties-of-the-lsd1-inhibitor-bomedemstat-in-preclinical-models
#29
JOURNAL ARTICLE
Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Jennifer Dias, Cassandra A Celatka, Amy E Tapper, Maria Kleppe, Mayuko Kanayama, Yuezhou Jing, Valentina Speranzini, Yuzhuo Z Wang, Jun Luo, Bruce J Trock, Samuel R Denmeade, Michael A Carducci, Andrea Mattevi, Hugh Y Rienhoff, John T Isaacs, W Nathaniel Brennen
INTRODUCTION: Lysine-specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration-resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis-targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes...
April 15, 2024: Prostate
https://read.qxmd.com/read/38618871/sources-of-pharmacokinetic-and-pharmacodynamic-variability-and-clinical-pharmacology-studies-of-antiseizure-medications-in-the-pediatric-population
#30
REVIEW
Patricia D Maglalang, Jiali Wen, Christoph P Hornik, Daniel Gonzalez
Multiple treatment options exist for children with epilepsy, including surgery, dietary therapies, neurostimulation, and antiseizure medications (ASMs). ASMs are the first line of therapy, and more than 30 ASMs have U.S. Food and Drug Administration (FDA) approval for the treatment of various epilepsy and seizure types in children. Given the extensive FDA approval of ASMs in children, it is crucial to consider how the physiological and developmental changes throughout childhood may impact drug disposition. Various sources of pharmacokinetic (PK) variability from different extrinsic and intrinsic factors such as patients' size, age, drug-drug interactions, and drug formulation could result in suboptimal dosing of ASMs...
April 2024: Clinical and Translational Science
https://read.qxmd.com/read/38612661/applications-of-flow-cytometry-in-drug-discovery-and-translational-research
#31
REVIEW
Sumana Ullas, Charles Sinclair
Flow cytometry is a mainstay technique in cell biology research, where it is used for phenotypic analysis of mixed cell populations. Quantitative approaches have unlocked a deeper value of flow cytometry in drug discovery research. As the number of drug modalities and druggable mechanisms increases, there is an increasing drive to identify meaningful biomarkers, evaluate the relationship between pharmacokinetics and pharmacodynamics (PK/PD), and translate these insights into the evaluation of patients enrolled in early clinical trials...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38607350/bioanalytical-approaches-to-support-the-development-of-antibody-oligonucleotide-conjugate-aoc-therapeutic-proteins
#32
REVIEW
Anthony Murphy, Ryan Hill, Michael Berna
RNA interference (RNAi) is a biological process that evolved to protect eukaryotic organisms from foreign genes delivered by viruses. This process has been adapted as a powerful tool to treat numerous diseases through the delivery of small-interfering RNAs (siRNAs) to target cells to alter aberrant gene expression.Antibody-oligonucleotide conjugates (AOCs) are monoclonal antibodies with complexed siRNA or antisense oligonucleotides (ASOs) that have emerged to address some of the challenges faced by naked or chemically conjugated siRNA, which include rapid clearance from systemic circulation and lack of selective delivery of siRNA to target cells...
April 12, 2024: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://read.qxmd.com/read/38596468/lung-microdialysis-and-in-vivo-pk-pd-integration-of-cefquinome-against-actinobacillus-pleuropneumoniae-in-a-porcine-experimental-lung-infection-model
#33
JOURNAL ARTICLE
Yuqin Chen, Min Li, Dehai Su, Shiyu Xiong, Youshu Feng, Qin Deng, Huanzhong Ding
This study aim to explore the application of microdialysis in pharmacokinetic (PK) and pharmacodynamic (PD) integration of cefquinome against Actinobacillus pleuropneumoniae in a porcine experimental lung infection model. The model was established via intratracheal inoculation where average bacterial counts (CFU) in the lungs of infected pigs reached 6.57 log10 CFU/g after 3 h. The PK profiles of unbound cefquinome in lung dialysates were determined following intramuscular injection of single doses of 0...
2024: Frontiers in Veterinary Science
https://read.qxmd.com/read/38595918/dosing-optimization-of-rituximab-for-primary-membranous-nephropathy-by-population-pharmacokinetic-and-pharmacodynamic-study
#34
JOURNAL ARTICLE
Hao Liang, Zhenling Deng, Shu Niu, Weijie Kong, Yang Liu, Song Wang, Haiyan Li, Yue Wang, Danxia Zheng, Dongyang Liu
Primary membranous nephropathy (PMN) is the most common cause for adult nephrotic syndrome. Rituximab has demonstrated promising clinical efficacy by random controlled trials and the off-label use is widely adopted in PMN. However, the standard dosage is borrowed from B cell lymphoma treatment with far more antigens and is oversaturated for PMN treatment, accompanied with additional safety risk and unnecessary medical cost. More than 15% serious adverse events were observed under standard dosage and low dose therapies were explored recently...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38593348/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-ras-driven-cancers
#35
JOURNAL ARTICLE
Jingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, Yingyun Wang, Matthew Holderfield, Ida Aronchik, Ian P Winters, Zeena Salman, Cristina Blaj, Marie Menard, Jens Brodbeck, Zhe Chen, Xing Wei, Michael J Rosen, Yevgeniy Gindin, Bianca J Lee, James W Evans, Stephanie Chang, Zhican Wang, Kyle J Seamon, Dylan Parsons, James Cregg, Abby Marquez, Aidan C A Tomlinson, Jason K Yano, John E Knox, Elsa Quintana, Andrew J Aguirre, Kathryn C Arbour, Abby Reed, W Clay Gustafson, Adrian L Gill, Elena S Koltun, David Wildes, Jacqueline A M Smith, Zhengping Wang, Mallika Singh
UNLABELLED: RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models...
April 9, 2024: Cancer Discovery
https://read.qxmd.com/read/38587080/prophylactic-efficacy-of-an-intranasal-spray-with-2-synergetic-antibodies-neutralizing-omicron
#36
JOURNAL ARTICLE
Xinghai Zhang, Feiyang Luo, Huajun Zhang, Hangtian Guo, Junhui Zhou, Tingting Li, Shaohong Chen, Shuyi Song, Meiying Shen, Yan Wu, Yan Gao, Xiaojian Han, Yingming Wang, Chao Hu, Xiaodong Zhao, Huilin Guo, Dazhi Zhang, Yuchi Lu, Wei Wang, Kai Wang, Ni Tang, Tengchuan Jin, Menglu Ding, Shuhui Luo, Cuicui Lin, Tingting Lu, Bingxia Lu, Yang Tian, Chengyong Yang, Guofeng Cheng, Haitao Yang, Aishun Jin, Xiaoyun Ji, Rui Gong, Sandra Chiu, Ailong Huang
BACKGROUNDAs Omicron is prompted to replicate in the upper airway, neutralizing antibodies (NAbs) delivered through inhalation might inhibit early-stage infection in the respiratory tract. Thus, elucidating the prophylactic efficacy of NAbs via nasal spray addresses an important clinical need.METHODSThe applicable potential of a nasal spray cocktail containing 2 NAbs was characterized by testing its neutralizing potency, synergetic neutralizing mechanism, emergency protective and therapeutic efficacy in a hamster model, and pharmacokinetics/pharmacodynamic (PK/PD) in human nasal cavity...
April 8, 2024: JCI Insight
https://read.qxmd.com/read/38583254/pi3k%C3%AE-and-mtor-dual-inhibitors-design-synthesis-and-anticancer-evaluation-of-3-substituted-aminomethylquinoline-analogues
#37
JOURNAL ARTICLE
Digambar Yevale, Nishith Teraiya, Twinkle Lalwani, Mayur Dalasaniya, Khushal Kapadiya, Rakesh Kumar Ameta, Chetan B Sangani, Yong-Tao Duan
Phosphatidylinositide-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) have recently been identified as potential cancer targets. In our work, a new family of quinoline analogues was designed, developed, and evaluated as dual inhibitors of PI3Kδ/mTOR. The preliminary biological activity analysis led to the discovery of the lead compounds 5h and 5e. Compounds 5h and 5e exhibited excellent anti-tumor potency with IC50 of 0.26 µM and 0.34 µM against Ramos cells, respectively...
March 30, 2024: Bioorganic Chemistry
https://read.qxmd.com/read/38578533/model-based-comparison-of-subcutaneous-versus-sublingual-apomorphine-administration-in-the-treatment-of-motor-fluctuations-in-parkinson-s-disease
#38
JOURNAL ARTICLE
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse, Zare Melyan, Jonathan Rubin
The objective of this study was to compare the effectiveness of subcutaneous (SC) and sublingual (SL) formulations of apomorphine for the treatment of motor fluctuations in Parkinson's disease using a pharmacokinetics (PK)/pharmacodynamics (PD) modeling approach. The PK of SC and SL apomorphine are best described by a one-compartment model with first-order absorption and a two-compartment model with delayed absorption, respectively. The PK/PD model relating apomorphine plasma concentrations to the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores was described by a sigmoidal Emax model assuming effective concentration = drug concentration in an effect compartment...
April 5, 2024: Journal of Pharmacokinetics and Pharmacodynamics
https://read.qxmd.com/read/38573940/continuous-evaluation-of-single-dose-moxifloxacin-concentrations-in-brain-extracellular-fluid-cerebrospinal-fluid-and-plasma-a-novel-porcine-model
#39
JOURNAL ARTICLE
T Mariager, J H Terkelsen, M Bue, K Öbrink-Hansen, R Nau, C R Bjarkam, H Nielsen, J Bodilsen
BACKGROUND: Knowledge regarding CNS pharmacokinetics of moxifloxacin is limited, with unknown consequences for patients with meningitis caused by bacteria resistant to beta-lactams or caused by TB. OBJECTIVE: (i) To develop a novel porcine model for continuous investigation of moxifloxacin concentrations within brain extracellular fluid (ECF), CSF and plasma using microdialysis, and (ii) to compare these findings to the pharmacokinetic/pharmacodynamic (PK/PD) target against TB...
April 4, 2024: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/38563414/pharmacokinetics-pharmacodynamics-and-safety-of-fesomersen-a-novel-antisense-inhibitor-of-factor-xi-in-healthy-chinese-japanese-and-caucasian-volunteers
#40
JOURNAL ARTICLE
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently available anticoagulants. Fesomersen is a conjugated antisense oligonucleotide that selectively inhibits the expression of FXI. The article describes three clinical studies that investigated the safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of fesomersen after subcutaneous (s...
April 2024: Clinical and Translational Science
keyword
keyword
48137
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.